Migraine Headache Clinical Trials 2023

Browse 8 Migraine Headache Medical Studies Across 8 Cities

1 Phase 3 Trial · 9 Migraine Headache Clinics

Clinical TrialsMigraine Headache Clinical Trials 2023
Reviewed by Michael Gill, B. Sc.
Image of Harbor-UCLA Medical Center in Torrance, United States.

Buccal Prochlorperazinefor Migraine

18 - 65
All Sexes
Torrance, CA
Headache is a common presenting complaint to the emergency department accounting for 1-2% of patient visits. Of these headaches, approximately 90% are migraine, tension headache, or combined presentations. The most commonly used migraine therapy in the ED is intravenous prochlorperazine, but its administration requires close nursing observation, a bed, and the insertion of an intravenous catheter. Buccal prochlorperazine represents an alternative form of delivery that enables rapid achievement of therapeutic blood levels and may lead to symptom resolution. In a randomized, controlled, prospective study,the investigators plan to assess the efficacy of buccal versus intravenous prochlorperazine for the initial emergency department treatment of migraine headaches.
Phase 3
Waitlist Available
Harbor-UCLA Medical CenterDavid Tanen, MD
Image of The Neurological Research center, Inc in Bennington, United States.

1for Migraine

18 - 65
All Sexes
Bennington, VT
Migraine headache occurs frequently in women more than men and is associated with symptoms not only of significant pain but also of symptoms typically including of photophobia, phonophobia, nausea and vomiting. Many migraine patients report difficulty in cognition from lack of concentration, difficulty in word finding or inability to remember. Many of these cognitive symptoms seem to be independent of the pain intensity and may occur completely separately from the headache pain but can be disabling. It is likely that the frequency and importance of cognitive symptoms associated with migraine are underreported. The Mental Efficacy Workload Test (MEWT) is a computerized battery that is designed to be an efficient and accurate measure of cognition during migraine headache. Treximet is a new migraine treatment recently FDA approved for the treatment for the relief of acute migraine that may be effective for the cognitive symptoms for migraine patients who have a history of cognitive dysfunction during a migraine headache. The primary efficacy parameter is to evaluate the effectiveness of treatment with Treximet versus placebo in patients with acute migraine headache measuring neuropsychological function using the MEWT during the migraine and comparing that score with a prior MEWT score when the patient had no migraine symptoms. A double blind, placebo-controlled, crossover study was chosen so that each patient may be her or his own control. It is the intent of this study to determine the type and intensity of cognitive dysfunction associated with migraine headache and to what extent that Treximet may relieve the cognitive dysfunction in a safe and effective manner.
Waitlist Available
FDA Approved Drug
The Neurological Research center, IncKeith R Edwards, M.D.GlaxoSmithKline
Image of CR Darnall Army Medical Center in Ft. Hood, United States.

Treatmentfor Migraine

18 - 65
All Sexes
Ft. Hood, TX
: Headaches are a common complaint presenting to the emergency department (ED), accounting for 1-2% of all ED visits, with migraines as the second most common primary headache syndrome. Patients that ultimately present to the ED have failed outpatient therapy and exhibit severe and persistent symptoms. Treatment options have been traditionally with a parenteral opiod, generally Demerol. Unfortunately, patients with chronic painful conditions like migraines have been prone to dependency. In 1986, a nonopioid, compazine was noted serendipitously to relieve migraine headache pain. 1 Nonopioid regimens have evolved as standard therapy in the treatment of migrainne headache in the ED. Today, there are a number of nonopioid treatment options, but not without their own individual concerns. Ergotamine and dihydroergotamine are effective, but commonly cause nausea and vomiting. Sumatriptan is expensive has recurrence rate, is ineffective in about 20-30%, and is contra-indicated in patients with cardiac disease. Metoclopramide, a dopamine receptor antagonist, commonly used as an anti-emetic agent, has been widely studied for use with acute migraines. Its side effects include drowsiness and dystonic reactions. Compazine has been successfully used to treat migraine headaches for the past several decades, and has been accepted as standard treatment of headaches in the ED. 2 Its side effect profile includes extrapyramidal effects, dysphoria, drowsiness and akathisias. The ideal medication for treating headaches would have no addictive properties, few side effects, quick onset, be highly effective and have a low rate of recurrence. Somatostatin is known to have an inhibitory effect on a number of neuropetides, which have been implicated in migraine. Native somatostatin is an unstable compound and is broken down in minutes, but octreotide, a somatostatin analogue has a longer half life. Intravenous somatostatin has been shown to be as effective as ergotamine in the acute treatment of cluster headache. 3 The analgesic effect of octreotide with headaches associated with growth hormone secreting tumor has been established. 4 Five somatostatin receptors have been cloned with octreotide acting predominantely on sst2 and sst5. The distribution of sst2 within the central nervous system strongly suggests that this particular somatostatin receptor has a role in cranial nociception, being highly expressed in the trigeminal nucleus caudalis and periaqueductal grey. Kapicioglu et.al performed a double blind study comparing octreotide to placebo in treating migraine. They found there to be a significantly greater relief of pain with octreotide at 2 and 6 hours compared to placebo (76% vs 25%, p<0.02). They noted that 47% of those in the octreotide group had complete relief compared to no patients in the placebo group. They went on to note that those patients in the octreotide group had earlier relief of symptoms and no side effects. The only minor adverse event related to the administration of octreotide was a local reaction in 3 patients (18%). In a study performed recently in Netherlands, no clinically relevant changes in vital signs, routine chemistry, and urinalysis were observed with octreotide use. Electrocardiogram analyses showed no newly occurring or worsening of known cardiac abnormalities 2 and 24 h after injection with octreotide. 5 Levy et. al also compared octreotide to placebo in a double blinded study but found no difference. This was a poorly designed study, in that the patients treated themselves at home with an injection of either placebo or octreotide for 2 episodes of headache and recorded their level of pain relief at 2 hours. Matharu et. al also performed a double blind study comparing octreotide to placebo, but looking at cluster headaches rather than migraines. They found there to be a significant improvement with the use of octreotide over placebo (52% vs 36%). At Darnall Army Community Hospital the cost of 100 mcg Octreotide and10 mg Compazine, is $10.46, $2.02-8.00, respectively.
Phase 1 & 2
Waitlist Available
CR Darnall Army Medical CenterAlex Rosin, MD
8 Migraine Headache Clinical Trials Near Me
Top Hospitals for Migraine Headache Clinical Trials
Image of University Medical Center of El Paso in Texas.
University Medical Center of El Paso
El Paso
1Active Trials
0All Time Trials for Migraine Headache
2023First Migraine Headache Trial
Image of St. Luke's University Health Network in Pennsylvania.
St. Luke's University Health Network
Bethlehem
1Active Trials
0All Time Trials for Migraine Headache
2023First Migraine Headache Trial
Image of VA Connecticut Healthcare System in Connecticut.
VA Connecticut Healthcare System
West Haven
1Active Trials
0All Time Trials for Migraine Headache
2023First Migraine Headache Trial
Image of Corona Doctors Medical Clinics Inc in California.
Corona Doctors Medical Clinics Inc
Corona
1Active Trials
0All Time Trials for Migraine Headache
2023First Migraine Headache Trial
Image of Harbor-UCLA Medical Center in California.
Harbor-UCLA Medical Center
Torrance
1Active Trials
0All Time Trials for Migraine Headache
2023First Migraine Headache Trial
Top Cities for Migraine Headache Clinical Trials
Image of Louisville in Kentucky.
Louisville
2Active Trials
Norton Children's HospitalTop Active Site
Image of El Paso in Texas.
El Paso
1Active Trials
University Medical Center of El PasoTop Active Site
Migraine Headache Clinical Trials by Phase of Trial
N/A Migraine Headache Clinical Trials
3Active Migraine Headache Clinical Trials
3Number of Unique Treatments
3Number of Active Locations
Osteopathic Manipulative Therapy (OMT)Auricular Acupuncture1
Migraine Headache Clinical Trials by Age Group
< 65 Migraine Headache Clinical Trials
1Active Migraine Headache Clinical Trials
Auricular Acupuncture
Most Recent Migraine Headache Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Dexamethasone for Migraine
8/28/2023
Phase < 1
Psilocybin for Migraine
8/10/2021
Phase 1
Osteopathic Manipulative Therapy (OMT) for Migraine
10/2/2018
N/A
Dexamethasone,Lidocaine,Thiamine cohort for Migraine
7/1/2017
Phase 1 & 2
Buccal Prochlorperazine for Migraine
4/1/2016
Phase 3
Top Treatments for Migraine Headache Clinical Trials
Treatment Name
Active Migraine Headache Clinical Trials
All Time Trials for Migraine Headache
First Recorded Migraine Headache Trial
Dexamethasone
1
1
2023
Osteopathic Manipulative Therapy (OMT)
1
1
2018
Psilocybin
1
1
2021
Dexamethasone,Lidocaine,Thiamine cohort
1
1
2017
Buccal Prochlorperazine
1
1
2016

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 5th, 2023

References1 Voigt K, Liebnitzky J, Burmeister U, Sihvonen-Riemenschneider H, Beck M, Voigt R, Bergmann A. Efficacy of osteopathic manipulative treatment of female patients with migraine: results of a randomized controlled trial. J Altern Complement Med. 2011 Mar;17(3):225-30. doi: 10.1089/acm.2009.0673. Epub 2011 Mar 8. https://pubmed.ncbi.nlm.nih.gov/213850862 McReynolds TM, Sheridan BJ. Intramuscular ketorolac versus osteopathic manipulative treatment in the management of acute neck pain in the emergency department: a randomized clinical trial. J Am Osteopath Assoc. 2005 Feb;105(2):57-68. https://pubmed.ncbi.nlm.nih.gov/157849283 Burch R, Rizzoli P, Loder E. The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies. Headache. 2018 Apr;58(4):496-505. doi: 10.1111/head.13281. Epub 2018 Mar 12. https://pubmed.ncbi.nlm.nih.gov/295276774 Zein-Hammoud M, Standley PR. Modeled Osteopathic Manipulative Treatments: A Review of Their in Vitro Effects on Fibroblast Tissue Preparations. J Am Osteopath Assoc. 2015 Aug;115(8):490-502. doi: 10.7556/jaoa.2015.103. Review. https://pubmed.ncbi.nlm.nih.gov/262148225 Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992 Jan 1;267(1):64-9. https://pubmed.ncbi.nlm.nih.gov/17271986 Zein-Hammoud M, Standley PR. Modeled Osteopathic Manipulative Treatments: A Review of Their in Vitro Effects on Fibroblast Tissue Preparations. J Am Osteopath Assoc. 2015 Aug;115(8):490-502. doi: 10.7556/jaoa.2015.103. https://pubmed.ncbi.nlm.nih.gov/262148227 Yadav UC, Subramanyam S, Ramana KV. Prevention of endotoxin-induced uveitis in rats by benfotiamine, a lipophilic analogue of vitamin B1. Invest Ophthalmol Vis Sci. 2009 May;50(5):2276-82. doi: 10.1167/iovs.08-2816. Epub 2009 Jan 10. https://pubmed.ncbi.nlm.nih.gov/191366988 Hayashi Y. Effects of intra-amygdaloid injections of alpha-difluoromethylornithine and putrescine on the development of electrical kindling in rats. Brain Res. 1991 Sep 27;560(1-2):181-5. https://pubmed.ncbi.nlm.nih.gov/17607269 Desjardins P, Butterworth RF. Role of mitochondrial dysfunction and oxidative stress in the pathogenesis of selective neuronal loss in Wernicke's encephalopathy. Mol Neurobiol. 2005;31(1-3):17-25. doi: 10.1385/MN:31:1-3:017. https://pubmed.ncbi.nlm.nih.gov/1595380910 Johri S, Shetty S, Soni A, Kumar S. Anaphylaxis from intravenous thiamine--long forgotten? Am J Emerg Med. 2000 Sep;18(5):642-3. doi: 10.1016/s0735-6757(00)90303-6. No abstract available. https://pubmed.ncbi.nlm.nih.gov/10999594
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top